Post-translational modifications and immune responses in liver cancer
暂无分享,去创建一个
[1] Chenyang Han,et al. LncRNA PSCK6-AS1-HIPK2 promotes Th1 differentiation via STAT1 phosphorylation to regulate colitis-related mucosal barrier damage. , 2023, International immunopharmacology.
[2] L. Butterfield,et al. Polyunsaturated Fatty Acid–Bound α-Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism , 2023, Cancer Research.
[3] M. Jücker,et al. The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism , 2023, International journal of molecular sciences.
[4] Jianfei Huang,et al. KRTCAP2 as an immunological and prognostic biomarker of hepatocellular carcinoma. , 2023, Colloids and surfaces. B, Biointerfaces.
[5] Ying-Ying Li,et al. Elevation of spermine remodels immunosuppressive microenvironment through driving the modification of PD-L1 in hepatocellular carcinoma , 2022, Cell Communication and Signaling.
[6] Juejin Wang,et al. Association of gut microbiome and primary liver cancer: A two‐sample Mendelian randomization and case–control study , 2022, Liver international : official journal of the International Association for the Study of the Liver.
[7] Q. Zhang,et al. IL-2–mTORC1 signaling coordinates the STAT1/T-bet axis to ensure Th1 cell differentiation and anti-bacterial immune response in fish , 2022, PLoS pathogens.
[8] M. Caligiuri,et al. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. , 2022, Trends in immunology.
[9] J. Ferlay,et al. Global burden of primary liver cancer in 2020 and predictions to 2040 , 2022, Journal of hepatology.
[10] C. Pang,et al. Post-translational modifications on the retinoblastoma protein , 2022, Journal of Biomedical Science.
[11] Xiaolong Yan,et al. Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy , 2022, Frontiers in Immunology.
[12] Xinglu Huang,et al. Combining Doxorubicin-Conjugated Polymeric Nanoparticles and 5-Aminolevulinic Acid for Enhancing Radiotherapy against Lung Cancer. , 2022, Bioconjugate chemistry.
[13] G. Wang,et al. Mechanism of cancer stemness maintenance in human liver cancer , 2022, Cell death & disease.
[14] M. Mariappan,et al. A second chance for protein targeting/folding: Ubiquitination and deubiquitination of nascent proteins , 2022, BioEssays : news and reviews in molecular, cellular and developmental biology.
[15] L. Nath,et al. Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma. , 2022, Current cancer drug targets.
[16] P. Khare,et al. Role of interleukin-17 in human papillomavirus infection and associated malignancies. , 2021, Microbial pathogenesis.
[17] Xinyi Li,et al. Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy , 2021, International journal of molecular sciences.
[18] Tieliang Ma,et al. Dexmedetomidine Directs T Helper Cells toward Th1 Cell Differentiation via the STAT1-T-Bet Pathway , 2021, BioMed research international.
[19] Y. Pathak,et al. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions , 2021, Frontiers in Immunology.
[20] F. Pan,et al. Post-Translational Regulations of Foxp3 in Treg Cells and Their Therapeutic Applications , 2021, Frontiers in Immunology.
[21] Pravir Kumar,et al. Post-translational modifications: Regulators of neurodegenerative proteinopathies , 2021, Ageing Research Reviews.
[22] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[23] I. Wertz,et al. Ubiquitination in the regulation of inflammatory cell death and cancer , 2021, Cell Death & Differentiation.
[24] D. Nayak,et al. Role of Host-Mediated Post-Translational Modifications (PTMs) in RNA Virus Pathogenesis , 2020, International journal of molecular sciences.
[25] Haojun Yang,et al. Involvement and Targeted Intervention of Mortalin-Regulated Proteome Phosphorylated-Modification in Hepatocellular Carcinoma , 2020, Frontiers in Oncology.
[26] E. Yeh,et al. SUMO: From Bench to Bedside. , 2020, Physiological reviews.
[27] N. Tang,et al. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1 , 2020, Journal for ImmunoTherapy of Cancer.
[28] Jeffrey S. Miller,et al. Exploring the NK cell platform for cancer immunotherapy , 2020, Nature Reviews Clinical Oncology.
[29] Matthias J. Feige,et al. Influence of glycosylation on IL-12 family cytokine biogenesis and function. , 2020, Molecular immunology.
[30] P. Wei,et al. Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. , 2020, Immunity.
[31] Dawang Zhou,et al. Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment. , 2020, Molecular cell.
[32] Qingjiao Li,et al. MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing , 2020, Nature Communications.
[33] Zhuanchang Wu,et al. Tim-3 hampers tumor surveillance of liver resident and conventional NK cells by disrupting PI3K signaling. , 2019, Cancer research.
[34] P. Adusumilli,et al. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. , 2019, Cancer cell.
[35] Manal M. Hassan,et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. , 2019, The Journal of clinical investigation.
[36] B. Shi,et al. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma , 2019, The Journal of Immunology.
[37] Clare C. Davies,et al. PRMTs and Arginine Methylation: Cancer's Best-Kept Secret? , 2019, Trends in molecular medicine.
[38] Hong Tang,et al. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression , 2019, Journal of Hematology & Oncology.
[39] Jing Wang,et al. The deubiquitinase Otub1 controls the activation of CD8 T cells and NK cells by regulating IL-15-mediated priming , 2019, Nature Immunology.
[40] Yun Yang,et al. SIRT1 inhibits hepatocellular carcinoma metastasis by promoting M1 macrophage polarization via NF-κB pathway , 2019, OncoTargets and therapy.
[41] J. Jang,et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization , 2019, Scientific Reports.
[42] Yulin Zhao,et al. RETRACTED ARTICLE: NEAT1 regulates Th2 cell development by targeting STAT6 for degradation , 2019, Cell cycle.
[43] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[44] Yu Xue,et al. PTMD: A Database of Human Disease-associated Post-translational Modifications , 2018, Genom. Proteom. Bioinform..
[45] M. Tao,et al. Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment , 2018, Oncoimmunology.
[46] Peng Li,et al. New peptide MY1340 revert the inhibition effect of VEGF on dendritic cells differentiation and maturation via blocking VEGF‐NRP‐1 axis and inhibit tumor growth in vivo , 2018, International immunopharmacology.
[47] Leo Swadling,et al. IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction , 2018, Front. Immunol..
[48] J. Zhao,et al. Change in the Treg/Th17 cell imbalance in hepatocellular carcinoma patients and its clinical value , 2017, Medicine.
[49] Giuseppe Troiano,et al. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review) , 2017, International journal of molecular medicine.
[50] Wei Jia,et al. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion , 2017, Nature Communications.
[51] K. Guo,et al. Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells , 2017, Oncology letters.
[52] L. Hui,et al. STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma. , 2015, The Journal of clinical investigation.
[53] Charles Bailey,et al. Phosphorylation of Single Stranded RNA Virus Proteins and Potential for Novel Therapeutic Strategies , 2015, Viruses.
[54] J. Abastado,et al. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression , 2015, Oncotarget.
[55] Seung-Hwan Lee,et al. IL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells , 2015, Front. Immunol..
[56] Z. Tian,et al. Re-examining the origin and function of liver-resident NK cells. , 2015, Trends in immunology.
[57] L. Butterfield,et al. Tumor-Derived α-Fetoprotein Impairs the Differentiation and T Cell Stimulatory Activity of Human Dendritic Cells , 2014, The Journal of Immunology.
[58] A. Ciechanover,et al. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. 1978. , 2012, Biochemical and Biophysical Research Communications - BBRC.
[59] L. Hurton,et al. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.
[60] Alicia M Bielik,et al. Identification and characterization of protein glycosylation using specific endo- and exoglycosidases. , 2011, Journal of visualized experiments : JoVE.
[61] Q. Gao,et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma , 2011, Molecular Cancer.
[62] M. Wolfert,et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine , 2011, Proceedings of the National Academy of Sciences.
[63] D. Ye,et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2 , 2011, Oncogene.
[64] R. Deshaies,et al. RING domain E3 ubiquitin ligases. , 2009, Annual review of biochemistry.
[65] A. Philpott,et al. Ubiquitylation on Canonical and Non-canonical Sites Targets the Transcription Factor Neurogenin for Ubiquitin-mediated Proteolysis* , 2009, The Journal of Biological Chemistry.
[66] Thomas Korn,et al. IL-17 and Th17 Cells. , 2009, Annual review of immunology.
[67] M. Caligiuri,et al. Human natural killer cells. , 2008, Blood.
[68] P. Allavena,et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.
[69] W. Paul,et al. Stat6 Is Necessary and Sufficient for IL-4’s Role in Th2 Differentiation and Cell Expansion , 2001, The Journal of Immunology.
[70] D. Cantrell. Phosphoinositide 3-kinase signalling pathways. , 2001, Journal of cell science.
[71] G. Trinchieri,et al. Biosynthesis and Posttranslational Regulation of Human IL-121 , 2000, The Journal of Immunology.
[72] M. Gately,et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. , 1995, Journal of immunology.
[73] R. Vessella,et al. Evaluation of AFP glycosylation heterogeneity in cancer patients with AFP‐producing tumors , 1984, International journal of cancer.
[74] A. Hershko,et al. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. , 1978, Biochemical and biophysical research communications.
[75] P. Murray. Macrophage Polarization. , 2017, Annual review of physiology.
[76] S. Ha,et al. Poster Session 4 : Immunology ; Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T Lymphocyte responses for DNA immunization , 2003 .